TY - CHAP M1 - Book, Section TI - Women and Ischemic Heart Disease A1 - Shaw, Leslee J. A1 - Taqueti, Viviany R. A1 - Wenger, Nanette K. A2 - Fuster, Valentin A2 - Narula, Jagat A2 - Vaishnava, Prashant A2 - Leon, Martin B. A2 - Callans, David J. A2 - Rumsfeld, John S. A2 - Poppas, Athena PY - 2022 T2 - Fuster and Hurst's The Heart, 15e AB - Chapter SummaryThis chapter highlights the evidence on sex differences in the pathophysiology and clinical presentations of ischemic heart disease (IHD), and identifies significant disparities in primary prevention and both stable and acute management strategies contributing to the often-reported high adverse risk for women. Throughout the 20th century, atherosclerotic cardiovascular disease (ASCVD) was viewed as predominantly a disease of older-aged men, and little information was available regarding its impact on women. Recent decades have witnessed emerging attention to ASCVD in women, with consequent research hypotheses focused on data specific to women. Today, there exists growing evidence on sex differences in prevention, presentation, diagnostic evaluation, management, and clinical outcomes of women compared with men with suspected and known IHD. The gamut of cultural, social, and financial differences among women and men profoundly impact prompt diagnosis, clinical management, and outcomes of at-risk women. Goals for reducing ASCVD risk tailored to women remain underexplored. The role of biology, clinical and population needs of women, and the socioeconomic disparities of females remain sizeable hurdles to effecting changes to the large population of young to older women at risk for ASCVD (see Fuster and Hurst’s Central Illustration). SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accessmedicine.mhmedical.com/content.aspx?aid=1202453805 ER -